Dr. Younes on 2016 ASH Highlights in Mantle Cell Lymphoma

Anas Younes, MD
Published: Wednesday, Dec 14, 2016



Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer, discusses highlights from the 2016 ASH Annual Meeting focused on the area of mantle cell lymphoma (MCL).

Most data presented in this field, he explains, were early and were in phase I/II. However, findings of one randomized study will likely change standard practice. This study compared the outcomes of young patients who received autologous stem cell transplant (ASCT) with either rituximab (Rituxan) maintenance for 3 years or observation. The patients who were on the rituximab arm had improved progression-free survival, event-free survival, and overall survival.

This is likely to change the standard of care for patients with MCL who are receiving ASCT, Younes says.


Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer, discusses highlights from the 2016 ASH Annual Meeting focused on the area of mantle cell lymphoma (MCL).

Most data presented in this field, he explains, were early and were in phase I/II. However, findings of one randomized study will likely change standard practice. This study compared the outcomes of young patients who received autologous stem cell transplant (ASCT) with either rituximab (Rituxan) maintenance for 3 years or observation. The patients who were on the rituximab arm had improved progression-free survival, event-free survival, and overall survival.

This is likely to change the standard of care for patients with MCL who are receiving ASCT, Younes says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x